ENTPD3 and neoplasm: From a perspective beyond traditional biomarkers, the presence status of ENTPD3+ CAFs in CRC patients was likely a natural mapping of the balance between the body’s anti-tumor immune system and the constantly changing tumor immune microenvironment.